Prostate Cancer

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of ​first-line niraparib plus abiraterone acetate and prednisone in mHSPC.

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

David Olmos, MD, PhD, discusses CAPTURE study findings on the prevalence of HRR mutations in mHSPC, highlighting prognostic impact and outcomes.

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.

Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.

Matthew R. Smith, MD, PhD, discusses findings from the ARANOTE trial that confirm the efficacy of darolutamide plus ADT in mCSPC.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

The FDA accepted the NDA seeking the approval of a new formulation of piflufolastat F 18 in prostate cancer.

The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.